BRIEF

on SANOFI-AVENTIS (EPA:SAN)

Sanofi obtains European approval for its VaxRabeo vaccine

Stock price chart of SANOFI-AVENTIS (EPA:SAN) showing fluctuations.

Sanofi has announced the European Commission's approval of its new rabies vaccine, VaxRabeo. This vaccine is intended for all age groups for pre-exposure and post-exposure prophylaxis. Manufactured using Vero cell technology, VaxRabeo offers improved thermostability and a longer shelf life compared to existing vaccines. Rabies, a deadly disease transmitted through the saliva of infected animals, causes approximately 59,000 deaths annually. This innovative vaccine from Sanofi helps strengthen protection against this disease, thanks to a rigorous clinical program that has demonstrated its safety and efficacy.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SANOFI-AVENTIS news